ENTRY       D00353                      Drug
NAME        Lamivudine (JAN/USP/INN);
            Epivir (TN)
  ABBR      3TC
PRODUCT     EPIVIR (GlaxoSmithKline LLC)
            EPIVIR (ViiV Healthcare Company)
  GENERIC   LAMIVUDINE (American Health Packaging)
            LAMIVUDINE (Apotex Corp.)
            LAMIVUDINE (Apotex Corp.)
            LAMIVUDINE (Aurobindo Pharma Limited)
            LAMIVUDINE (Aurobindo Pharma Limited)
            LAMIVUDINE (Camber Pharmaceuticals)
            LAMIVUDINE (Camber Pharmaceuticals)
            LAMIVUDINE (Camber Pharmaceuticals)
            LAMIVUDINE (Chartwell RX)
            LAMIVUDINE (Cipla USA)
            LAMIVUDINE (Golden State Medical Supply)
            LAMIVUDINE (Ingenus Pharmaceuticals)
            LAMIVUDINE (Lannett Company)
            LAMIVUDINE (Lupin Pharmaceuticals)
            LAMIVUDINE (Macleods Pharmaceuticals Limited)
            LAMIVUDINE (Major Pharmaceuticals)
            LAMIVUDINE (Prasco Laboratories)
            LAMIVUDINE (Rising Health)
            LAMIVUDINE (Strides Pharma Science Limited)
FORMULA     C8H11N3O3S
EXACT_MASS  229.0521
MOL_WEIGHT  229.2562
CLASS       Antiviral
             DG01890  Nucleoside reverse transcriptase inhibitor (NRTI)
             DG03107  Anti-HIV agent
              DG01656  HIV reverse transcriptase inhibitor
            Transporter substrate
             DG02859  SLC22A6 substrate
REMARK      Same as: C07065
            Therapeutic category: 6250
            ATC code: J05AF05
            Product: D00353<JP/US>
            Product (mixture): D07507<JP/US> D08775<JP/US> D10600<JP/US> D10838<US> D11392<US> D11395<US> D11396<US> D11522<JP/US>
EFFICACY    Antiviral, Reverse transcriptase inhibitor
  DISEASE   HIV-1 infection [DS:H01563]
            Hepatitis B [DS:H00412]
TARGET      HBV reverse transcriptase [KO:K21037]
            HIV-1 reverse transcriptase [KO:K24802]
  PATHWAY   ko03230(K21037+K24802)  Viral genome structure
            ko03240(K21037+K24802)  Viral replication
            ko03250(K24802)  Viral life cycle - HIV-1
            ko05161(K21037)  Hepatitis B
METABOLISM  Transporter: SLC22A6 [HSA:9356]
INTERACTION  
STR_MAP     map07044  Antiviral agents
            map07053  Anti-HIV agents
OTHER_MAP   map04976  Bile secretion
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
                 J05AF05 Lamivudine
                  D00353  Lamivudine (JAN/USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-hepatitis B (HBV) Agents
               Lamivudine
                D00353  Lamivudine (JAN/USP/INN)
              Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTI)
               Lamivudine
                D00353  Lamivudine (JAN/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D00353  Lamivudine (JAN/USP/INN)
            Drug groups [BR:br08330]
             Antiviral
              DG01890  Nucleoside reverse transcriptase inhibitor (NRTI)
               D00353  Lamivudine
              DG03107  Anti-HIV agent
               DG01656  HIV reverse transcriptase inhibitor
                D00353  Lamivudine
             Transporter substrate
              DG02859  SLC22A6 substrate
               D00353  Lamivudine
            Drug classes [BR:br08332]
             Antiviral
              DG03107  Anti-HIV agent
               D00353  Lamivudine
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               HBV reverse transcriptase inhibitor
                D00353  Lamivudine (JAN/USP/INN) &lt;JP/US&gt;
            Antimicrobials abbreviations [BR:br08327]
             Antivirals
              Genome replication inhibitor
               HBV reverse transcriptase inhibitor
                D00353  Lamivudine (JAN/USP/INN)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D00353
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D00353
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug transporters
              D00353
DBLINKS     CAS: 134678-17-4
            PubChem: 7847419
            ChEBI: 63577
            PDB-CCD: 3TC
            LigandBox: D00353
            NIKKAJI: J457.051K
ATOM        15
            1   C1y C    19.1100  -17.9200
            2   O2x O    17.9900  -17.0800
            3   C1x C    18.6900  -19.2500
            4   C1y C    16.8700  -17.9200
            5   S2x S    17.2900  -19.2500
            6   C1b C    15.6800  -17.2900
            7   O1a O    14.3500  -18.1300
            8   C8x C    20.3000  -15.8200
            9   N4y N    20.3000  -17.2200
            10  C8y C    21.4900  -17.9200
            11  N5x N    22.7500  -17.2200
            12  C8y C    22.7500  -15.8200
            13  C8x C    21.4900  -15.1200
            14  O5x O    21.4900  -19.3200
            15  N1a N    23.9400  -15.1200
BOND        16
            1     1   2 1
            2     1   3 1
            3     2   4 1
            4     3   5 1
            5     4   6 1 #Down
            6     6   7 1
            7     4   5 1
            8     8   9 1
            9     9  10 1
            10   10  11 1
            11   11  12 2
            12   12  13 1
            13    8  13 2
            14    1   9 1 #Down
            15   10  14 2
            16   12  15 1
///
